The drug failed to improve progression-free survival in mesothelioma, causing the stocks of Bayer’s collaborators ImmunoGen and MorphoSys to slip.

Fresh from the news that its lead pipeline candidate is back under FDA review with a verdict due before year-end, Aeterna has just announced the departure of…

Check out Friday's dose of biotech's news of note.

The positive narrative spun by Ironwood’s management failed to convince investors, who seized on perceived underwhelming efficacy data.

The dumping of LSD1 inhibitor ORY-1001 wiped as much as 30% off Oryzon’s stock price as investors digested the loss of the $500 million-plus deal.

NeuroVia gets $14 million to treat rare CNS disorder X-linked adrenoleukodystrophy.

The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva.

Check out the rest of Wednesday's news of note.

Eli Lilly likes what it sees in Adimab's antibody R&D platform, opting to roll it out at sites in San Diego and New York to help its antibody…

R&D